Early Access — free while we kick the tires
EdgarHawk

KNSA Kiniksa Pharmaceuticals International, plc Insider Trading

Latest: CMO Sold $3.1M of Shares · May 2026
1 filing analyzed · Latest 2026-05-05
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling
May 2026
2026-05-05
medium
Paolini John F. Sell
CHIEF MEDICAL OFFICER
58,424 shares
$3,137,823
@ $53.71
Significance 5/10

CMO John F. Paolini nets ~$3.1M selling majority stake while simultaneously buying stock at lower price

Paolini, Kiniksa's Chief Medical Officer, executed a complex transaction pattern on the same day: a small opportunistic buy of lower-priced shares paired with substantial sales of holdings at current market levels—netting over $3 million in proceeds. This mixed activity doesn't fit the typical insider-conviction narrative; rather, it looks like disciplined portfolio rebalancing by someone with deep operational knowledge. The timing is notable: the stock is trading at its 52-week highs following a rapid recovery, yet Paolini is trimming his position while the company is profitable with accelerating revenue growth. His decision to sell near the peak while the fundamentals remain strong and the valuation appears stretched suggests a focus on risk management—not panic, but prudent profit-taking by a C-suite executive. The smaller buy component may reflect confidence in the company's long-term trajectory, even as he reduces near-term exposure.

More Chemicals and Allied Products companies

Get alerts for KNSA

Add KNSA to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access